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Background: To ensure that clinical practice guidelines (CPGs) form a sound basis for decision-making in health
care, it is necessary to be able to reliably assess and ensure their quality. This results in the need to assess the content
of guidelines systematically, particularly with regard to the validity of their recommendations.
The aim of the present analysis was to determine the suitability and applicability of frequently used assessment tools
for evidence syntheses with regard to the assessment of guideline content.
Methods: We conducted a systematic comparison and analysis of established tools for the assessment of evidence
syntheses (guidelines, systematic reviews, health technology assessments). The tools analyzed were: ADAPTE, AGREE II,
AMSTAR, GLIA and the INAHTA checklist. We analyzed methodological steps related to the assessment of the reliability
and validity of guideline recommendations. Data were extracted and analyzed by two persons independently of one
another.
Results: Widely used tools for the methodological assessment of evidence syntheses are not suitable for a
comprehensive content-related assessment. They remain mostly at the level of assessment of the documentation
of processes. Some tools assess selected content-related aspects, but operationalization is either unspecific or lacking.
Conclusion: None of the tools analyzed enables the structured and comprehensive assessment of the content of
guideline recommendations with special regard to their reliability and validity. All tools contribute towards the judicious
use of evidence syntheses by supporting their systematic development or assessment. However, further progress is
needed, particularly with regard to the assessment of content quality. This includes comprehensive operationalization
and documentation of the assessment process to ensure reliability and validity, and therefore to enable the effective use
of trustworthy guidelines in the health care system.
Keywords: Practice guidelines as topic/standards, Decision making, Quality in health care, Guideline quality, Guideline
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According to the current definition by the Institute of
Medicine (IOM), clinical practice guidelines (CPGs) “are
statements that include recommendations intended to
optimize patient care that are informed by a systematic
review of evidence and an assessment of the benefits and
harms of alternative care options” [1]. They are viewed as* Correspondence: michaela.eikermann@uni-wh.de
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article, unless otherwise stated.tools for making health care decisions more rational, with
the ultimate aim of improving the quality and effectiveness
of care [2].
To ensure that guidelines form a sound basis for
decision-making and standards in health care, it is ne-
cessary to be able to reliably assess and ensure their
quality. Although methods for guideline development
are being further elaborated [1,3,4], there still seems
to be a need to increase adherence to these standards
[5]. Guidelines still show substantial differences in their de-
velopment process, reporting, methodological quality and,
not least, in content [6-13], and many recommendationstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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crucial issue of managing conflicts of interest of guideline
panel members has so far not been sufficiently resolved
[5,15]. In addition to the assessment of the development
methods, the current inadequacies result in the need
to assess the content of guidelines systematically with
regard to the appropriate implementation of methodo-
logical standards and particularly to the reliability of
their recommendations.
In the last few years there have been numerous initia-
tives to improve the quality of guidelines. As a result, vari-
ous tools with different objectives have been created in the
fields of both guideline development and assessment. In
respect of guideline development and adaptation, the
activities of the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) Working Group
and the ADAPTE Collaboration are of particular note
[4,16-19]. A range of tools are available to assess the
quality of guidelines. We identified 40 different tools in
a systematic search [20]. The one most widely used
internationally is the AGREE instrument (Appraisal of
Guidelines for Research & Evaluation) [21] and its re-
vised version, AGREE II [22-24]. In addition, a translated
and amended version of AGREE, the German Instrument
for Methodological Guideline Appraisal (DELBI) [25],
is available for use in the German health care system.
However, the tools focus on methodological issues around
guideline development and reporting, and none of them
appears to be suited to conduct a complete, systematic
and content-related analysis of guideline recommenda-
tions, which seems to be essential to ensure that recom-
mendations are reliable and valid [26,27].
There is still a need for development here, especially
as high methodological quality does not necessarily cor-
relate with high content quality [28]. To provide tools for
the assessment of the content of guidelines, particularly
concerning the validity of their recommendations, the de-
velopment of a further assessment tool therefore suggests
itself. However, in view of the effort involved, it would be
meaningful first to examine systematically to what extent
an assessment of content quality can be conducted by
means of existing tools for the assessment of evidence
syntheses, in particular guidelines, but also systematic
reviews or Health Technology Assessments (HTAs).
The aim of the present analysis was to determine the
suitability and applicability of frequently used assessment
tools for evidence syntheses with regard to the assessment
of guideline content, namely, the appropriate implementa-
tion of methodological standards and particularly the reli-
ability of recommendations.
Methods
The present paper is based on the following definitions
by the IOM:Validity: Practice guidelines are valid if, when followed,
they lead to the health and cost outcomes projected for
them, with other things being equal. A prospective as-
sessment of validity will consider the projected health
outcomes and costs of alternative courses of action, the
relationship between the evidence and recommendations,
the substance and quality of the scientific and clinical
evidence cited, and the means used to evaluate the evi-
dence [1].
Reliability/Reproducibility: Practice guidelines are reli-
able and reproducible: (1) if—given the same evidence and
methods for guidelines development—another set of ex-
perts would produce essentially the same statements; and
(2) if—given the same circumstances—the guidelines are
interpreted and applied consistently by practitioners or
other appropriate parties. A prospective assessment of
reliability may consider the results of independent ex-
ternal reviews and pretests of guidelines [1].
Assessment tools analyzed
We conducted a systematic comparison and analysis of
selected established tools for the development and assess-
ment of evidence syntheses. On the basis of a systematic
search from another project [20] we included the follow-
ing guideline-specific tools: ADAPTE (assessment module
from the ADAPTE Manual and Toolkit) [16], AGREE II
(Appraisal of Guidelines for Research and Evaluation)
[22,23] and GLIA (GuideLine Implementability Appraisal)
[29,30]. Furthermore, we included AMSTAR (A Measure-
ment Tool to Assess Systematic Reviews) [31] and the
INAHTA checklist [32,33] as assessment tools for system-
atic reviews and HTAs. This is because our main focus
was on the appropriate implementation of methodological
standards, which can also be an issue in systematic reviews
or HTAs. Besides this the inclusion of these tools in our
analysis was suggested by guidelines experts in numerous
discussions on conferences or internal workshops.
Due to the numerous tools available for the assessment
of evidence syntheses [20,34,35], we decided to focus the
analysis on the current, established and most commonly
used ones, which we identified in the context of our
previous review [20] and which are mostly validated
(Additional file 1). They are often based on or represent
further developments of former tools; an analysis of
former tools therefore seemed superfluous. Furthermore,
a complete analysis of all available tools is not feasible
within an acceptable period of time and with an acceptable
use of resources.
Analysis criteria
We summarized aspects regarding the assessment of con-
tent quality, which are already integral parts of the com-
monly used assessment tools, and which could form the
basis for the development of tools for the assessment of
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relating to the assurance or assessment of the validity of
guidelines or guideline recommendations. We made no
detailed analysis of methodological steps essentially related
to external factors influencing guideline validity; for ex-
ample, we did not check the suitability of a recommenda-
tion in a certain context or the correctness of the Grade of
Recommendation (GoR) awarded.
The following categories of the tools were analyzed:
 Characteristics of the tools– description
– rationale for development
– objective(s)
– answer and evaluation categories
– documentation of the assessment
– consequences of the assessment
 Components and operationalization of the
assessment. Assessment of the:– medical definitions
– thematic completeness
– unambiguity of the content of the recommendationTable 1 Characteristics of the tools analyzed
Basic characteristics
Specific tools for assessment of evidence synthesis
Guideline-specific tools (development or assessment)
Primary objective: assessment of guidelines
Validated tool
Individual recommendation or question is focus of the assessment
Extraction of data to be evaluated
Uniform format for answers
Explicit definition of “quality”
Explicit definition of “validity”
Assessment of quality
Aspects of methodological quality
Content-related aspects
Quality of the evidence base
Consequences of the assessment
Consequences for use of evidence base
Consequences for use of the whole guideline (e.g. recommendation
for use, suitability as a source)
Consequences for use of guideline recommendation or conclusion of
a systematic review / HTA (e.g. modification when used as a source)
*: with special focus on implementability.
†: content-related aspects (e.g. regarding the evidence base of the recommendatio– outcomes applied (especially with regard to
completeness and patient relevance)
– literature search and study selection
– evaluation and interpretation of the evidence base
– consensus process
Data were extracted and analyzed by two persons inde-
pendently of one another. Disagreements were resolved by
discussion. For each item we analyzed whether the tool
assessed the documentation of guideline development
as well as the content (by means of the appropriate im-
plementation of methods and the appropriateness of the
results). We also checked whether the steps for the assess-
ment of content were fully operationalized. We defined
“operationalization” as any information or guidance given
within the tools on how to assess the relevant item (e.g.
examples, instructions, rating matrices).
Results
Characteristics of the tools analyzed
The tools serve different purposes but have a common
goal, i.e. to ensure the high quality of guidelines or other
evidence syntheses (see Table 1).
AMSTAR and the INAHTA checklist are not targeted
towards guidelines, but are tools for assessing systematic
reviews or HTA reports. AGREE II and AMSTAR are toolsADAPTE AGREE II GLIA AMSTAR INAHTA
X X X X X
X X X − −
in part X X* − −
X X X X −
X − in part X X
in part − − − −
in part X in part X in part
X X − X −
X − X − −
X X X X X
X In part† X − X
X In part† In part − −
X − − − −
X X X n. a. n. a.
X − X − −
ns) are given as instructions to fill in the assessment form.
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has a special status, as it is a tool for guideline adaptation,
i.e. for the development of new guidelines on the basis of
pre-existing guidelines produced in a different setting, and
contains methods for their assessment. GLIA is a tool for
the assessment of the implementability of guidelines.
AGREE II, ADAPTE, GLIA and AMSTAR have been
validated [22,23,30,31,36-38].
The tools differ in their level of analysis. A distinction
can be made here as to whether they relate to the assess-
ment of a whole guideline/systematic review or to an in-
dividual recommendation or question. Assessments using
AGREE are consistently made at the level of the whole
guideline, while ADAPTE and GLIA are applied completely
or largely to an individual recommendation or question.
The extraction of the data to be evaluated is not con-
ducted in a uniform manner. No tool specifies the full
extraction of data; ADAPTE specifies partial extraction.
This does not apply to AGREE II, AMSTAR, GLIA and
the INAHTA checklist, where only the assessment itself is
documented and, if required, supplemented by comments.
Not all tools analyzed show a uniform format for an-
swers. For example, the assessment with AGREE II is
conducted by means of Likert scales, AMSTAR offers
4 possible answers, and ADAPTE specifies several pos-
sible answers for the individual assessment steps (e.g.
yes/no/unclear; 4-stage Likert scale: strongly agree –
strongly disagree.
Definition of quality
An explicit definition of quality is given in 2 tools
(AGREE and AMSTAR). They congruently name the pre-
vention of systematic errors in the development of guide-
lines or systematic reviews as a quality criterion.
Definition of validity
Only ADAPTE and GLIA provide definitions for the vari-
ous validity terms. Whereas ADAPTE defines scientific
validity (consistency between evidence, its interpretation
and recommendations), GLIA defines validity as the degree
to which the recommendation reflects the intent of the
developer and the strength of the evidence.
Assessment areas
According to the different objectives of the tools, various
aspects of the quality of a guideline/recommendation or
systematic review are captured.
In ADAPTE, the methodological assessment of guide-
lines is conducted, among other things, with AGREE.
Accordingly, AMSTAR can be used to assess the methodo-
logical quality of a systematic review. An assessment of
content-related aspects is also conducted in the ADAPTE
manual as well as to a very limited extent in AGREE II and
GLIA. The quality of evidence as such is examined neitherin the assessment of guideline quality with AGREE II, nor
in the assessment of the quality of systematic reviews with
AMSTAR. All guideline-specific tools contain questions
on the acceptance and applicability of the guideline or
recommendation.
Consequences of the assessment
In 3 of the 5 tools analyzed, the consequences that may
result from the assessment are described. AMSTAR and
the INAHTA checklist provide no information in this re-
spect. As shown in Table 1, an assessment with AGREE
II may lead to the rejection of guidelines or recommen-
dations or to their adoption with limitations. The assess-
ment with GLIA results in consequences related to the
focus of the tool: the implementability of a guideline.
Components and operationalization of the assessment
In a second step we analyzed the components of the
assessment, as well as the operationalization of the as-
sessment process. The analysis was performed from the
perspective of guideline assessment (see Table 2).
For every criterion we checked whether an assessment
of the documentation, as well as of content, was planned. If
the latter case applied, we analyzed whether the complete
operationalization of the process was specified in the tool
analyzed.
Assessment of medical definitions and unambiguity of
content
The basis of the assessment of the unambiguity and qual-
ity of the content of guideline recommendations is the
clear classification of patients, interventions and outcomes
according to the PICO formula. All definitions relevant in
this context must be clearly explained.
In AGREE II, ADAPTE and GLIA the assessment of the
medical definitions used in the guideline/recommendation
of interest is limited to an evaluation of their documenta-
tion. AMSTAR assesses whether the characteristics of the
studies included in the systematic review are presented; it
does not evaluate the documentation and unambiguity of
content of the definitions used in the systematic review
itself.
AGREE II only assesses the unambiguity of content for
the totality of recommendations in a guideline. ADAPTE
does not include an assessment going beyond this, nor
does AMSTAR assess the unambiguity of content of the
conclusions drawn in the systematic review of interest.
Assessment of the outcomes considered
The medical benefit of an intervention should relate to the
patient and therefore should ideally be assessed on the
basis of patient-relevant outcomes [39]; such outcomes
should therefore preferably be assessed and reported in
guideline recommendations.
Table 2 Content and operationalization of the assessment
ADAPTE AGREE II GLIA AMSTAR INAHTA-checklist
Assessment of the medical definitions used in
the guideline or systematic review of interest
Assessment of documentation x x x − −
Assessment of content − − − − −
Complete operationalization* n. a. n. a. n. a. n. a. n. a.
Assessment of the unambiguity of content of the
guideline recommendation or conclusion of the
systematic review/HTA
Assessment of content (x)‡,§ (x)‡ x − −
Complete operationalization x‡ x − n. a. n. a.
Assessment of outcomes considered Assessment of documentation (x)§,|| (x)|| − x −
Assessment of content –
completeness
− − − − −
Assessment of content –
patient relevance
x − − − −
Complete operationalization* − n. a. n. a. n. a. n. a.
Assessment of the literature search Assessment of documentation x x − x x
Assessment of content – currency x − − − −
Assessment of content –
completeness†
x x − − −
Assessment of content – plausibility x x − − −
Complete operationalization* − - n. a. n. a. n. a.
Assessment of study selection Assessment of documentation x x − x x
Assessment of content x x − x −
Complete operationalization* − − n. a. − n. a.
*: Regarding the assessment of content-related aspects. An item is rated as n.a. if no assessment of content is provided by the tools.
†: “Complete” also refers to the consideration of unpublished data.
‡: An assessment of the unambiguity of content of the totality of recommendations is made.
§: The assessment is made within the context of the AGREE assessment as a component of the ADAPTE toolkit.
||: Only indirect assessment of the documentation of outcomes.
Abbreviations: n. a.: not applicable.
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completeness and patient relevance of outcomes. AGREE
II indirectly assesses the documentation of outcomes con-
sidered in the guideline (aim of the guideline, key ques-
tions, monitoring and/or auditing criteria). However, no
complete operationalization is given for the definition of
relevant outcomes. ADAPTE also assesses the clinical
relevance of outcomes but does not specify how the
process is operationalized.
Assessment of the literature search and study selection
A systematic literature search is a key factor in the prep-
aration of high-quality evidence syntheses such as CPGs
or systematic reviews. Errors in the search strategy may
lead to incomplete identification of the relevant literature
[40]. The same applies to the erroneous exclusion of pub-
lications during the study selection process.
With respect to the literature search, we analyzed
whether the tools included an assessment of the com-
ponents of the search strategy applied, especially con-
cerning currency, completeness and plausibility. Such a
comprehensive assessment is prescribed in ADAPTE,
but it is not specified how this process is operationalized.
AMSTAR only describes the documentation of the search,but does not assess the components of the strategy itself.
AGREE II assesses the appropriateness of search strategies
but does not provide any further operationalization.
In respect of the completeness of the search, special
attention should be paid to whether unpublished data
were searched for. Limitation to published data may lead
to considerable bias in the evaluation of the evidence [41].
No tool explicitly described how to handle unpublished
data. However, AMSTAR assesses how potential publica-
tion bias is considered in guidelines and systematic reviews.
All tools, with the exception of GLIA, include questions
on the documentation of study selection. AMSTAR also
addresses the systematic exclusion of literature by means
of publication type. Additionally, ADAPTE assesses the
suitability of inclusion and exclusion criteria, but does not
specify how this process is operationalized.
Assessment of the quality rating of the evidence base
The guideline or review authors’ quality rating of the evi-
dence base covers the evaluation and interpretation of the
literature underlying the respective recommendation or
conclusion.
ADAPTE, GLIA and AMSTAR include questions on
how the quality of the evidence base is rated and on the
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mendations. These relate in part to an assessment of docu-
mentation, but also in varying depth of detail to aspects of
content.
However, for many points the assessment tools fail to
mention how the process is operationalized. AGREE II
makes only a general assessment for the whole guideline
or, more specifically, for the whole body of evidence as
to whether benefits and risks were considered in the
formulation of the recommendations or the strength
and limitations of the body of evidence.
Assessment of the consensus process
The consensus process is an elementary component in the
generation and formulation of guideline recommendations.
Especially in cases where evidence is lacking or conflicting
evidence is available, and recommendations are made or
grades of recommendation allocated on the basis of a con-
sensus decision, a properly conducted consensus process is
essential.
ADAPTE and AGREE II include questions on the docu-
mentation of the consensus process. This criterion is not
applicable to AMSTAR and the INAHTA checklist.
AGREE II, ADAPTE, AMSTAR, GLIA and the INAHTA
checklist are tools that can contribute towards improving
the quality of guidelines and other evidence syntheses, such
as systematic reviews or HTA reports, by supporting the
systematic development or assessment of these publica-
tions. The tools analyzed are not suitable for a compre-
hensive assessment of the content of guidelines or other
evidence syntheses, and often remain at the level of the as-
sessment of the documentation of processes. Further
evaluation in the sense of an assessment of content with
regard to the reliability and validity of recommendations
and conclusions is only performed to a limited degree or
is lacking. In addition, the operationalization of the assess-
ment process is either unspecific or completely absent.
Nevertheless, with the development of AGREE II, includ-
ing the addition of item 9. “The strength and limitations
of the body of evidence are clearly described”, an import-
ant step was taken towards a more content-related assess-
ment and therefore towards an assessment of guideline
reliability and validity.
Discussion
We conducted a systematic comparison and analysis of
established tools for the assessment of evidence synthe-
ses to identify components for content assessment. Our
results were to support the development of comprehen-
sive tools for content assessment. Basically, the question
can be posed as to why an assessment of guideline con-
tent and other secondary literature is necessary at all,
and whether an assessment of methodological quality
would be sufficient. One reason is that, even thoughrequirements and recommendations for guideline devel-
opment, as well as tools for the assessment of methodo-
logical quality, have existed for some years, guideline
recommendations and systematic reviews on comparable
questions vary widely [13,42]. Especially when system de-
cisions are based on guideline recommendations, it should
be ensured that these recommendations form a sound
basis for decision-making, which at least necessitates the
assessment of their content.
Some guideline assessment tools, such as AGREE II,
require an independent external review in order to im-
prove guideline quality. The IOM describes the external
review as one of the standards for trustworthy CPGs [1].
Furthermore, a description of the methodology used to
conduct the external review should be presented, for ex-
ample, in AGREE II [24]. This seems to be a crucial point:
How to perform an external review of guideline content
only on the basis of the documentation of guideline meth-
odology and without standards for content assessment.
The analysis presented here forms part of the further
development of guideline assessment tools with a focus
on the assessment of guideline content. The analysis
criteria examined were defined within the framework of
this development. We decided to focus on the identifi-
cation, selection and interpretation of the evidence. Never-
theless, other aspects may influence the reliability and
validity of guidelines and the interpretation of evidence,
for example, the handling of competing interests of guide-
line panel members. Established tools were specifically
chosen for this analysis. A comparison such as the one
performed can serve to highlight both differences and
new approaches. However, it is not suited to examine
whether all relevant criteria for the assessment of guideline
content were actually considered, especially since the ana-
lysis criteria selected have so far not been discussed with
external researchers. The tools presented in this paper
differ in their objectives. Therefore the absence of cer-
tain components cannot be generally viewed as a deficit
of these tools, as this is not only due to the different
objectives but partially to variations in requirements,
especially concerning applicability. In particular, this should
be viewed against the background that none of the tools an-
alyzed was developed to explicitly address the assessment
of guideline content. Nevertheless, it is surprising that the
assessment of guideline content still plays a subordinate
role compared to the assessment of guideline methodology,
even though the limitations of a purely methodological
assessment have been known for years [11,27].
Individual aspects of guideline quality, such as the iden-
tification and inclusion of unpublished data, have become
increasingly important in recent years, but have so far
been insufficiently addressed in the tools analyzed. It is to
be expected that this issue will be addressed in assessment
tools in the future.
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key questions and recommendations. It is therefore
surprising that up to now, most guideline assessment
tools focus on the whole guideline, instead of on the
single recommendations or key questions.
The main limitation of our analysis is that we did not
analyze all available assessment tools for guidelines and
other secondary literature. On the basis of our systematic
search for guideline assessment tools [20] and on an HTA
report on quality assessment tools [34,35], we identified
40 tools for guideline assessment and 15 for the assess-
ment of systematic reviews. A comprehensive data extrac-
tion and analysis of all these tools would have been far
beyond our resources. Nevertheless, we analyzed the
established tools most commonly used in their specific
area.
Conclusion
None of the tools analyzed enables the structured and
comprehensive assessment of the content of guideline
recommendations with special regard to their reliability
and validity. Those available are almost exclusively de-
signed to assess guidelines at the level of the develop-
ment process and to assess the documentation of this
process. There is thus a need for further progress here.
The approach to be adopted should be compatible with
existing tools in the field of guideline development and
assessment and should close gaps, particularly with re-
gard to the comprehensive operationalization and docu-
mentation of the assessment process. Driven by idealistic
concepts, developers and users of CPGs need practically
applicable tools for the assessment of guideline content
to ensure reliability and validity and therefore to enable
the effective use of guidelines in the health care system.
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